Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults

Abstract

In HIV-infected subjects who have received little or no prior antiretroviral therapy, treatment with abacavir alone or in combination with ZDV is well tolerated and resulted in sustained improvements in key immunologic and virologic efficacy parameters through 12 weeks.